
Coya Therapeutics, Inc.: updates and filings
Price
$2.95
November 20, 2026Market cap $69M
What Ploutos Investor adds for Coya Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Oct 14, 2026Other material eventsForm8-K
- Oct 5, 2026Other material eventsForm8-K
- Sep 15, 2026Other material eventsForm8-K
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Aug 7, 2026Officer or director change (amendment)Form8-K/A
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 25, 2026Shareholder voteForm8-K
- May 13, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- May 13, 2026Additional annual meeting materialFormDEFA14A
- May 13, 2026Annual meeting proxy statementFormDEF 14A
- May 12, 2026Material agreement enteredForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operations, other material eventsForm8-K
- Apr 2, 2026Officer or director changeForm8-K
- Mar 20, 2026FilingFormEFFECT
- Mar 19, 2026Correspondence with the SECFormCORRESP
- Mar 19, 2026Letter from the SECFormUPLOAD
- Mar 16, 2026Shelf registration for future offeringsFormS-3
- Mar 16, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 16, 2026Results of operationsForm8-K
- Mar 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jan 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Oct 14, 2026 | 8-K | Other material events | Document |
| Oct 5, 2026 | 8-K | Other material events | Document |
| Sep 15, 2026 | 8-K | Other material events | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Aug 7, 2026 | 8-K/A | Officer or director change (amendment) | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 25, 2026 | 8-K | Shareholder vote | Document |
| May 13, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| May 13, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 13, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| May 12, 2026 | 8-K | Material agreement entered | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations, other material events | Document |
| Apr 2, 2026 | 8-K | Officer or director change | Document |
| Mar 20, 2026 | EFFECT | Filing | Document |
| Mar 19, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 19, 2026 | UPLOAD | Letter from the SEC | Document |
| Mar 16, 2026 | S-3 | Shelf registration for future offerings | Document |
| Mar 16, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 16, 2026 | 8-K | Results of operations | Document |
| Mar 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jan 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 5, 2021.
The full analysis
What do Coya Therapeutics's filings show?
The filings are where every one of Coya Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.